跳至主要内容
临床试验/EUCTR2010-022867-37-DE
EUCTR2010-022867-37-DE进行中(未招募)不适用

A randomized, double-blind, placebo-controlled trial of the efficacy and safety of DEB025/Alisporivir in combination with peg-IFNalpha2a and ribavirin in hepatitis C genotype 1 treatment-naïve - NA

ovartis Pharma Services AG0 个研究点目标入组 1,040 人开始时间: 2011年5月9日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
1,040

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • -Chronic hepatitis C viral
  • -HCV genotype
  • -no previous treatment for hepatitis C infection
  • -Serum HCV RNA level = 1000 IU/ml assessed by quantitative polymerase chain reaction or equivalent at screening, no upper limit.
  • -liver evaluation prior to Baseline: liver biopsy within 3 years or Fibroscan within 6 months.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range: 0
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Key exclusion criteria are :
  • -HCV genotype different from genotype 1 or co-infection with other HCV genotype.
  • -co-infection with Hepatitis B or HIV
  • -Any other cause of relevant liver disease other than HCV
  • -Presence or history of hepatic decompensation
  • -ALT = 10 times ULN,
  • - more than 1 episode of elevated bilirubin (>ULN) in past 6 months
  • Other protocol-defined inclusion/exclusion criteria may apply

研究者

相似试验